Recurrent immunoglobulin A nephropathy after renal transplantation: a significant contributor to graft loss.
Standard
Recurrent immunoglobulin A nephropathy after renal transplantation: a significant contributor to graft loss. / Ohmacht, C; Kliem, V; Burg, M; Nashan, Björn; Schlitt, H J; Brunkhorst, R; Koch, K M; Floege, J.
in: TRANSPLANTATION, Jahrgang 64, Nr. 10, 10, 1997, S. 1493-1496.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Recurrent immunoglobulin A nephropathy after renal transplantation: a significant contributor to graft loss.
AU - Ohmacht, C
AU - Kliem, V
AU - Burg, M
AU - Nashan, Björn
AU - Schlitt, H J
AU - Brunkhorst, R
AU - Koch, K M
AU - Floege, J
PY - 1997
Y1 - 1997
N2 - BACKGROUND: Although most transplanted patients with underlying IgA nephropathy (IgAN) develop histological recurrence, its clinical relevance is considered low. METHODS: We performed a single-center analysis of 61 renal transplant patients with IgAN. RESULTS: Forty-four percent of the patients showed a stable graft function. Progressive graft dysfunction apparently due to recurrent IgAN occurred in 23% of the patients (16% required dialysis). Five patients were retransplanted, and three again developed dialysis-dependent renal failure apparently due to recurrent IgAN. In 20% of the patients, chronic transplant dysfunction was due to other reasons, whereas no reason was identified in 13% of the patients. Neither findings before transplantation, the ACE genotype, the type of immunosuppression, nor the course after transplantation predicted transplant dysfunction due to recurrent IgAN. Follow-up after transplantation was longer in the group with dysfunction due to recurrent disease than in the group with dysfunction due to chronic rejection or in the stable group. CONCLUSION: Recurrent IgAN is a clinically relevant problem in renal transplant patients. Its importance may have been underestimated in the past due to inadequate lengths of follow-up.
AB - BACKGROUND: Although most transplanted patients with underlying IgA nephropathy (IgAN) develop histological recurrence, its clinical relevance is considered low. METHODS: We performed a single-center analysis of 61 renal transplant patients with IgAN. RESULTS: Forty-four percent of the patients showed a stable graft function. Progressive graft dysfunction apparently due to recurrent IgAN occurred in 23% of the patients (16% required dialysis). Five patients were retransplanted, and three again developed dialysis-dependent renal failure apparently due to recurrent IgAN. In 20% of the patients, chronic transplant dysfunction was due to other reasons, whereas no reason was identified in 13% of the patients. Neither findings before transplantation, the ACE genotype, the type of immunosuppression, nor the course after transplantation predicted transplant dysfunction due to recurrent IgAN. Follow-up after transplantation was longer in the group with dysfunction due to recurrent disease than in the group with dysfunction due to chronic rejection or in the stable group. CONCLUSION: Recurrent IgAN is a clinically relevant problem in renal transplant patients. Its importance may have been underestimated in the past due to inadequate lengths of follow-up.
M3 - SCORING: Zeitschriftenaufsatz
VL - 64
SP - 1493
EP - 1496
JO - TRANSPLANTATION
JF - TRANSPLANTATION
SN - 0041-1337
IS - 10
M1 - 10
ER -
